FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors
Single-arm study: 61 participants, 26 weeks; no thromboembolic events observed.
Hermans et al.
doi.org/10.1016/j.jt...
